Cost-effectiveness analysis of enzyme replacement therapy (ERT) for treatment of infantile-onset Pompe disease (IOPD) in the Iranian pharmaceutical market.

Hashempour, Reza; Davari, Majid; Pourreza, Abolghasem; Alaei, Mohammadreza; Ahmadi, Batoul

Hashempour, Reza; Davari, Majid; Pourreza, Abolghasem; Alaei, Mohammadreza; Ahmadi, Batoul.

Afiliação

Hashempour R; Department of Health Management and Economics, School of Public Health, Tehran University of Medical Science, Tehran, Iran.
Davari M; Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Science, Tehran, Iran.
Pourreza A; Pharmaceutical Management & Economics Research Center, Tehran University of Medical Science, Tehran, Iran.
Alaei M; Department of Health Management and Economics, School of Public Health, Tehran University of Medical Science, Tehran, Iran.
Ahmadi B; Department of Pediatric Endocrinology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Intractable Rare Dis Res ; 9(3): 130-136, 2020 Aug.

Article em En | MEDLINE | ID: mdl-32844068

Palavras-chave

Iran; Myozyme; Pompe disease; cost-effectiveness; enzyme replacement therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Prognostic_studies / Systematic_reviews Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google